Torcetrapib in Patients With Below-Average HDL-C on a Background of Atorvastatin - Torcetrapib in Patients With Below-Average HDL-C on a Background of Atorvastatin

Description:

The goal of the trial was to evaluate the safety and efficacy of treatment with torcetrapib, a cholesteryl ester transfer protein inhibitor, in patients with below-average high-density lipoprotein cholesterol (HDL-C) also treated with atorvastatin.